Evvy lands $40 million Series B to boost vaginal microbiome research

Women’s‑health technology firm Evvy announced on Tuesday that it has closed a $40 million Series B financing round, with Catalio Capital Management serving as the lead investor, TechCrunch reported. The capital injection follows a seed round that helped the company build its initial microbiome‑sequencing pipeline and launch a pilot cohort of users across the United States.

In addition to Catalio, the round attracted participation from several existing backers, including existing investors who have been supporting Evvy since its inception. While the full list of participants was not disclosed, the funding will be allocated toward expanding the company’s longitudinal data set, hiring additional scientists, and scaling its mobile platform that enables users to submit self‑collected vaginal swabs for analysis.

Evvy’s core offering combines at‑home sampling kits with a cloud‑based analytics engine that maps the composition of the vaginal microbiome over time. By aggregating anonymized data from thousands of participants, the startup aims to identify patterns linked to conditions such as bacterial vaginosis, yeast infections, and preterm birth risk. The company also plans to partner with pharmaceutical firms and academic researchers to accelerate the development of targeted therapies.

The vaginal microbiome has emerged as a critical frontier in women’s health research over the past decade. Historically, the area received limited funding compared with other microbiome niches, leaving gaps in understanding how microbial balance influences reproductive outcomes. Recent studies published in top medical journals have shown that dysbiosis—an imbalance of bacterial species—can affect fertility, pregnancy complications, and susceptibility to infections. As a result, venture capital interest in microbiome‑focused health tech has risen sharply, with investors seeking data‑rich platforms that can de‑risk drug development and personalize treatment.

Looking ahead, Evvy intends to use the new capital to broaden its user base, incorporate machine‑learning models that predict health events, and pursue regulatory clearances that could enable its platform to be used as a diagnostic aid. If successful, the company could provide clinicians with real‑time insights, potentially reducing the reliance on invasive exams and improving outcomes for millions of women.

The infusion of $40 million underscores a growing confidence among investors that data‑driven approaches to women’s health can generate both scientific breakthroughs and commercial returns. As Evvy scales, its work may help fill a longstanding research void while offering consumers more agency over their reproductive health.